NCT02267746 - A Study To Evaluate The Safety And Therapeutic Equivalence of Tazarotene Foam 0.1% in Subjects With Acne Vulgaris | Biotech Hunter

Enrollment

893

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

September 30, 2014

Study Completion Date

September 30, 2014

Conditions

Acne Vulgaris

Interventions

DRUG

Tazarotene (Fabior™)

DRUG

Tazarotene (Actavis)

DRUG

Vehicle foam

Trial Locations (15)

33027

FXM Research Miramar, Miramar

33126

LCC Medical Research Institute, Miami

33144

International Dermatology Research, Miami

33175

FXM Research Corp, Miami

33414

Atlantic Clinical Research Collaborative, Wellington

33511

Moore Clinical Research, Brandon

33609

Moore Clinical Research, Tampa

33618

Moore Clinical Research, Tampa

75093

Research Across America, Plano

75234

Research Across America, Dallas

84117

Dermatology Research Center, Salt Lake City

91436

Encino

94538

Center for Dermatology Clinical Research, Fremont

02886

Omega Medical Research, Warwick

Unknown

FXM International, Belize City